

News Releases

[Register for email alerts.](#)

All Categories

Archive



Date 12/28/15

Title

Valeant Announces J. Michael Pearson Will Be On Medical Leave of Absence

Download

[PDF](#)

Date 12/16/15

Title

Valeant Provides Financial Guidance Update

Download

[PDF](#)

Date 12/15/15

Title

Valeant Announces New U.S. Fulfillment Agreements With Walgreens; Plans To Further Extend Distribution To Independent Pharmacies

Download

[PDF](#)

Date 11/20/15

Title

Valeant To Hold Investor Day On December 16 (Updated)

Download

[PDF](#)

Date 11/12/15

Title

Valeant Pharmaceuticals To Present At Industry Conference

Download**PDF**

Date

11/09/15

Title

Valeant To Hold Conference Call For Investors To Provide Business Update

Download**PDF**

Date

11/06/15

Title

Valeant Issues Statement On Sales Of Company Stock

Download**PDF**

Date

10/30/15

Title

Former Deputy Attorney General Appointed To Advise Valeant's Ad Hoc Committee

Download**PDF**

Date

10/30/15

Title

Valeant To Terminate Relationship With Philidor

Download**PDF**

Date

10/26/15

Title

Statements Of J. Michael Pearson, Chairman And CEO, And Robert Ingram, Lead Outside Director Of Valeant Pharmaceuticals

Download**PDF**

Date

10/26/15

Title

Valeant Pharmaceuticals Confirms Appropriateness Of Accounting, Appoints Ad Hoc Board Committee To Review Philidor

Download

PDF

Date 10/26/15

Title

Valeant Pharmaceuticals Announces The Addition Of G. Mason Morfit To Its Board Of Directors

Download

PDF

Date 10/22/15

Title

Valeant Pharmaceuticals To Hold Investor Conference Call On October 26, 2015

Download

PDF

Date 10/21/15

Title

Valeant Pharmaceuticals Responds To Erroneous Report

Download

PDF

Date 10/19/15

Title

Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results

Download

PDF

Date 10/15/15

Title

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Synergetics USA, Inc.

Download

PDF

Date 10/15/15

Title

Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Synergetics USA, Inc.

Download

PDF

Date 10/14/15

Title

Valeant Provides Update Regarding Government Inquiries

Download[PDF](#)**Date**

10/13/15

Title

Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant

Download[PDF](#)**Date**

10/05/15

Title

Valeant Pharmaceuticals To Announce 2015 Third Quarter Results On October 19, 2015

Download[PDF](#)**Date**

10/05/15

Title

Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Synergetics USA, Inc.

Download[PDF](#)**Date**

09/22/15

Title

Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Novel Glaucoma Candidate VESNEO™ (latanoprostene bunod)

Download[PDF](#)**Date**

09/08/15

Title

Valeant And Progenics Announce FDA Acceptance Of NDA Submission For Oral RELISTOR®

Download[PDF](#)**Date**

09/02/15

Title

Valeant Pharmaceuticals To Acquire Synergetics USA

Download[PDF](#)**Date**

09/01/15

Title

Valeant And AstraZeneca To Partner On Brodalumab

Download[PDF](#)**Date**

08/25/15

Title

Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale To Its Board Of Directors

Download[PDF](#)**Date**

08/20/15

Title

Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals

Download[PDF](#)**Date**

07/23/15

Title

Valeant Pharmaceuticals Reports Second Quarter 2015 Financial Results

Download[PDF](#)**Date**

07/17/15

Title

Valeant Pharmaceuticals Agrees To Acquire Amoun Pharmaceutical

Download[PDF](#)**Date**

06/24/15

Title

Valeant Pharmaceuticals To Announce 2015 Second Quarter Results On July 23, 2015

Download

PDF

Date 06/23/15

Title

Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR®

Download

PDF

Date 06/11/15

Title

Valeant Pharmaceuticals To Appoint Robert L. Rosiello As Chief Financial Officer

Download

PDF

Date 05/27/15

Title

Salix Announces FDA Approval of Xifaxan® 550 mg for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)

Download

PDF

Date 05/19/15

Title

Valeant Pharmaceuticals Announces 2015 Annual Meeting Results

Download

PDF

Date 05/12/15

Title

Valeant Pharmaceuticals To Webcast 2015 Annual Meeting Of Shareholders

Download

PDF

Date 04/29/15

Title

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results (PDF Version)

Download

PDF

Date 04/29/15

Title

Valeant Pharmaceuticals Reports First Quarter 2015 Financial Results

Download

PDF

Date 04/29/15

Title

Valeant Announces CFO Succession Plan And Additional Executive Appointment

Download

PDF

Date 04/24/15

Title

RELISTOR® Receives Positive CHMP Opinion in the EU for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain

Download

PDF

Date 04/09/15

Title

Valeant Pharmaceuticals To Announce 2015 First Quarter Results On April 29, 2015

Download

PDF

Date 04/01/15

Title

Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 2.75% Convertible Senior Notes Due 2015

Download

PDF

Date 04/01/15

Title

Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019

Download

PDF

Date 04/01/15

Title

Redemption of All of Salix's Outstanding 6.00% Senior Notes due 2021

Download**PDF**

Date

04/01/15

Title

Valeant Pharmaceuticals International, Inc. Completes Acquisition Of Salix Pharmaceuticals

Download**PDF**

Date

04/01/15

Title

Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix Pharmaceuticals, Ltd.

Download**PDF**

Date

03/27/15

Title

Valeant Pharmaceuticals Closes Offering Of \$1.45 Billion Of Common Shares

Download**PDF**

Date

03/17/15

Title

Valeant Pharmaceuticals Prices Offering Of \$1.45 Billion Of Common Shares

Download**PDF**

Date

03/16/15

Title

Valeant Pharmaceuticals Announces Offering Of \$1.45 Billion Of Common Shares

Download**PDF**

Date

03/16/15

Title

Valeant And Salix Agree On Amended Terms To Merger Agreement

Download

PDF

Date 03/13/15

Title

Valeant Announces HSR Clearance For Salix Acquisition

Download

PDF

Date 03/13/15

Title

Valeant Announces Pricing Of Private Offering Of Senior Notes

Download

PDF

Date 03/11/15

Title

Valeant Comments On Endo Offer To Acquire Salix

Download

PDF

Date 03/09/15

Title

Valeant Announces Launch Of Private Offering Of Senior Notes

Download

PDF

Date 02/25/15

Title

PROVENGE® (sipuleucel-T) Demonstrates Sustained Immune Response Two Years after Treatment in Biochemically-Recurrent Prostate Cancer

Download

PDF

Date 02/22/15

Title

Valeant To Acquire Salix Pharmaceuticals For \$158.00 Per Share In Cash

Download

PDF

Date 02/22/15

Title

Valeant Pharmaceuticals Reports Fourth Quarter And Full Year 2014 Financial Results

Download

[PDF](#)

Date 02/10/15

Title

Valeant Pharmaceuticals Announces Expiration Of Bid Deadline In Connection With Agreement To Acquire Assets From Dendreon

Download

[PDF](#)

Date 02/05/15

Title

Valeant Enters Into Amended Agreement To Remain Lead Bidder In Acquisition Of Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

Download

[PDF](#)

Date 02/05/15

Title

Valeant Pharmaceuticals To Announce 2014 Fourth Quarter And Full Year Results On February 24, 2015

Download

[PDF](#)

Date 01/29/15

Title

Valeant Selected As Lead Bidder To Acquire Dendreon And Its Leading Immunotherapy Treatment, PROVENGE® (sipuleucel-T)

Download

[PDF](#)

Date 01/20/15

Title

Bausch + Lomb Introduces New Software and Advanced OCT Imaging System for VICTUS® Femtosecond Laser Platform

Download

[PDF](#)

Date 01/15/15

Title

Valeant Announces Redemption of All of the Approximately \$500 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018

Download

[PDF](#)

Date 01/15/15

Title

Valeant Announces Pricing Of Private Offering Of Senior Notes

Download

[PDF](#)

Date 01/15/15

Title

Valeant Announces Launch of Private Offering of Senior Notes

Download

[PDF](#)

Date 01/06/15

Title

Valeant Pharmaceuticals To Present At The J.P. Morgan 2015 Healthcare Conference

Download

[PDF](#)



Investor Inquiries

ir@bauschhealth.com

877-281-6642

514-856-3855 (Canada)

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to
the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights
reserved. MTB.0230.USA.18 V2.0

Media inquiries

Corporate.communications@bauschhealth.com

908-569-3692

**CALIFORNIA RESIDENTS: DO NOT SELL MY
PERSONAL INFORMATION**

